Header Logo

JOSE ANTONIO KARAM

TitleAssociate Professor
InstitutionMD Anderson
DepartmentUrology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Tang C, Hara K, Sherry AD, Serrano AG, Kostousov LV, Hernandez SD, Lu W, Shen L, Shah AY, Jonasch E, Karam JA, Matin SF, Tannir N, Wang J, Msaouel P, Sircar K, Solis L. YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5). PMID: 38579843.
      Citations:    Fields:    
    2. Mbilinyi RH, Msaouel P, Rao P, Karam JA, Tannir NM, Tang C. Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study. Clin Genitourin Cancer. 2024 Mar 05; 102065. PMID: 38556389.
      Citations:    Fields:    
    3. Abdelsalam ME, Lu T, Baiomy A, Awad A, Odisio BC, Habibollahi P, Irwin D, Karam JA, Matin SF, Stafford J, Ahrar K. Magnetic resonance imaging-guided renal biopsy shows high safety and diagnostic yield: a tertiary cancer center experience. Eur Radiol. 2024 Feb 24. PMID: 38400904.
      Citations:    Fields:    
    4. Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274. Eur Urol Oncol. 2024 Apr; 7(2):302-303. PMID: 38000932.
      Citations:    Fields:    Translation:Humans
    5. Balderrama-Brondani V, Griffin AM, Owen TJ, Merriman KW, Chahla BB, Varghese J, Jimenez C, Waguespack SG, Graham PH, Perrier ND, Fisher SB, Karam JA, Shah AY, Campbell M, Hassan MM, Habra MA. Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer Registry. Endocr Pract. 2024 Jan; 30(1):25-30. PMID: 37858722.
      Citations:    Fields:    Translation:Humans
    6. Borges Dos Reis R, Shu X, Ye Y, Borregales L, Karam JA, Adibi M, Wu X, Reis LO, Wood CG. Urinary miRNAs Predict Metastasis in Patients With Clinically Localized Clear Cell Renal Cell Carcinoma Treated With Nephrectomy. Clin Genitourin Cancer. 2024 02; 22(1):e156-e162.e4. PMID: 37945405.
      Citations:    Fields:    Translation:Humans
    7. Abdelsalam ME, Hudspeth TN, Leonards L, Kusin SB, Buckley JR, Bassett R, Awad A, Karam JA, Matin SF, Lu T, Ahrar K. Effectiveness of Thermal Ablation for Renal Cell Carcinoma after Prior Partial Nephrectomy. Eur Urol Open Sci. 2023 Nov; 57:45-50. PMID: 38020520; PMCID: PMC10658406.
      Citations:    
    8. Esdaille AR, Karam JA, Master VA, Spiess PE, Raman JD, Sharma P, Shapiro DD, Das A, Sexton WJ, Zemp L, Patil D, Allen GO, Matin SF, Wood CG, Jason Abel E, Abel JE, Abel EJ. Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients. Urology. 2023 12; 182:168-174. PMID: 37690543.
      Citations:    Fields:    Translation:Humans
    9. Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2024 Apr; 7(2):266-274. PMID: 37442673.
      Citations: 1     Fields:    Translation:Humans
    10. Shapiro DD, Karam JA, Master VA, Sexton WJ, Matin SF, Spiess PE, Abel EJ. Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610. Eur Urol Oncol. 2023 12; 6(6):638-639. PMID: 37268448.
      Citations:    Fields:    
    11. Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun. 2023 05 10; 14(1):2684. PMID: 37164948; PMCID: PMC10172300.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    12. Shapiro DD, Karam JA, Master VA, Zemp LW, Sexton WJ, Matin SF, Spiess PE, Jason Abel E. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6. Eur Urol. 2023 08; 84(2):e55-e56. PMID: 37149462.
      Citations:    Fields:    Translation:Humans
    13. Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, He R, Westerman ME, Gao J, Rao P, Lam TNA, Jonasch E, Perelli L, Cheng EH, Carugo A, Heffernan TP, Walker CL, Genovese G, Tannir NM, Karam JA, Msaouel P. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med. 2023 05; 13(5):e1267. PMID: 37226898; PMCID: PMC10210052.
      Citations: 2     Fields:    Translation:Humans
    14. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus. 2023 09; 9(5):734-741. PMID: 36863962; PMCID: PMC10460829.
      Citations: 1     Fields:    
    15. Shapiro DD, Karam JA, Zemp L, Master VA, Sexton WJ, Ghasemzadeh A, Schmeusser BN, Davaro F, Peak T, Patil D, Matin S, Spiess PE, Abel EJ. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci. 2023 Apr; 50:43-46. PMID: 36861106; PMCID: PMC9969293.
      Citations: 1     
    16. Abdelsalam ME, Awad A, Baiomy A, Irwin D, Karam JA, Matin SF, Sheth RA, Habibollahi P, Odisio BC, Lu T, Ahrar K. Outcomes of Radiofrequency Ablation for Solitary T1a Renal Cell Carcinoma: A 20-Year Tertiary Cancer Center Experience. Cancers (Basel). 2023 Jan 31; 15(3). PMID: 36765867; PMCID: PMC9913388.
      Citations: 1     
    17. Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, Kassouf W, Mitchell T, Montironi R, O'Brien T, Panebianco V, Scelo G, Shuch B, van Poppel H, Blosser CD, Psutka SP. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol. 2022 11; 82(5):529-542. PMID: 36100483.
      Citations:    
    18. Msaouel P, Lee J, Karam JA, Thall PF. A Causal Framework for Making Individualized Treatment Decisions in Oncology. Cancers (Basel). 2022 Aug 14; 14(16). PMID: 36010916; PMCID: PMC9406391.
      Citations:    
    19. Moore JA, Lehner MJ, Anfossi S, Datar S, Tidwell RS, Campbell M, Shah AY, Ward JF, Karam JA, Wood CG, Pisters LL, Calin GA, Tu SM. Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeries. BJUI Compass. 2023 Jan; 4(1):81-87. PMID: 36569509; PMCID: PMC9766861.
      Citations:    
    20. Pollard AC, Paolillo V, Radaram B, Qureshy S, Li L, Maity T, Wang L, Uddin MN, Wood CG, Karam JA, Pagel MD, Piwnica-Worms D, Millward SW, Fowlkes NW, Norton W, Engel BJ, Pisaneschi F, Zacharias NM. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[18F]Fluoroglutamine. Mol Imaging Biol. 2022 12; 24(6):959-972. PMID: 35732988; PMCID: PMC9681699.
      Citations:    Fields:    
    21. Master VA, Uzzo RG, Bratlavsky G, Karam JA. Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond. Eur Urol Focus. 2022 05; 8(3):651-653. PMID: 35662502.
      Citations:    Fields:    
    22. Daher M, Varghese J, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MA. Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246. PMID: 35092681; PMCID: PMC9016449.
      Citations:    Fields:    Translation:Humans
    23. Bancos I, Daher M, Lee JE, Graham PH, Karam JA, Henriquez A, Mckenzie TJ, Sada A, Vaidya A, Abbondanza T, Kiernan CM, Rao SN, Hamidi O, Sachithanandan N, Habra MA, Srougi V, Bourdeau I, Poirier J, Hoff AO, Chambo JL, Almeida MQ, Fragoso MCBV. Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival. J Clin Endocrinol Metab. 2022 03 24; 107(4):964-971. PMID: 34850915; PMCID: PMC9122637.
      Citations:    Fields:    Translation:Humans
    24. Moore JA, Slack RS, Lehner MJ, Campbell MT, Shah AY, Zhang M, Guo CC, Ward JF, Karam JA, Wood CG, Pisters LL, Tu SM. Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers (Basel). 2022 Feb 23; 14(5). PMID: 35267435; PMCID: PMC8909729.
      Citations:    
    25. Westerman ME, Yevich SM, Dori Y, Ward JF, Pisters LL, Karam JA, Wood CG, Avritscher R, Matin SF. Lymphangioembolization for iatrogenic chylous ascites after retroperitoneal urological surgery. BJU Int. 2022 05; 129(5):585-587. PMID: 34962705.
      Citations:    Fields:    Translation:Humans
    26. Pieretti AC, Ozambela M, Westerman ME, Nogueras-Gonzalez GM, Segarra LA, Zacharias NM, Vaporciyan A, Hofstetter W, Huynh T, Aldousari S, Matin SF, Karam JA. Predictors of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. Clin Genitourin Cancer. 2022 08; 20(4):e330-e338. PMID: 35279419; PMCID: PMC9486579.
      Citations:    Fields:    Translation:Humans
    27. Howley BV, Mohanty B, Dalton A, Grelet S, Karam J, Dincman T, Howe PH. The ubiquitin E3 ligase ARIH1 regulates hnRNP E1 protein stability, EMT and breast cancer progression. Oncogene. 2022 03; 41(12):1679-1690. PMID: 35102251; PMCID: PMC8933277.
      Citations:    Fields:    Translation:HumansCells
    28. Falahkheirkhah K, Guo T, Hwang M, Tamboli P, Wood CG, Karam JA, Sircar K, Bhargava R. A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections. Lab Invest. 2022 05; 102(5):554-559. PMID: 34963688; PMCID: PMC9050807.
      Citations:    Fields:    Translation:Humans
    29. Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel). 2021 Nov 30; 13(23). PMID: 34885132; PMCID: PMC8656882.
      Citations: 2     
    30. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375. PMID: 34737281; PMCID: PMC8569213.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    31. Karam JA, Puligandla M, Flaherty KT, Uzzo RG, Matin SF, Pins MR, Wood CG, Kane C, Jewett MAS, Kim SE, Dutcher JP, DiPaola RS, Haas NB. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805. BJU Int. 2022 06; 129(6):718-722. PMID: 34480522; PMCID: PMC9423939.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    32. Pieretti AC, Shapiro DD, Westerman ME, Hwang H, Wang X, Segarra LA, Campbell MT, Tannir NM, Jonasch E, Matin SF, Wood CG, Karam JA. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol. 2021 12; 39(12):837.e9-837.e17. PMID: 34551888; PMCID: PMC9486901.
      Citations: 1     Fields:    Translation:Humans
    33. Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021 12; 19(6):e401-e408. PMID: 34625389.
      Citations: 1     Fields:    Translation:Humans
    34. Takahashi H, Vikram R, Jimenez RE, Bolan CW, Kawashima A, Karam JA, Takahashi N. MR characteristics of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: comparison with clear cell and papillary subtypes of renal cell carcinoma. Abdom Radiol (NY). 2021 11; 46(11):5250-5259. PMID: 34338814.
      Citations:    Fields:    Translation:Humans
    35. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2022 05; 129(5):610-620. PMID: 34228889; PMCID: PMC10097479.
      Citations: 1     Fields:    Translation:Humans
    36. Pieretti AC, Westerman ME, Childs A, Millward N, Shapiro DD, Sircar K, Rao P, Jonasch E, Campbell MT, Tannir NM, Matin SF, Wood CG, Karam JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. 2021 11; 39(11):790.e17-790.e23. PMID: 34301458.
      Citations:    Fields:    Translation:Humans
    37. Campbell SC, Uzzo RG, Karam JA, Chang SS, Clark PE, Souter L. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. J Urol. 2021 Aug; 206(2):209-218. PMID: 34115531.
      Citations: 10     Fields:    Translation:Humans
    38. Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol. 2021 Aug; 206(2):199-208. PMID: 34115547.
      Citations: 11     Fields:    Translation:Humans
    39. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Correction: Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2021 Jun 01; 27(11):3265. PMID: 34074655.
      Citations:    Fields:    
    40. McIntosh AG, Umbreit EC, Wood CG, Matin SF, Karam JA. Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy. Transl Androl Urol. 2021 May; 10(5):2233-2245. PMID: 34159106; PMCID: PMC8185683.
      Citations:    
    41. Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel). 2021 Apr 30; 13(9). PMID: 33946504; PMCID: PMC8124338.
      Citations: 2     
    42. Abdelsalam ME, Sabir SH, Ba SBK, Karam JA, Matin SF, Wood CG, Ahrar K. Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. AJR Am J Roentgenol. 2021 07; 217(1):157-163. PMID: 33909469.
      Citations:    Fields:    Translation:Humans
    43. Zacharias NM, Wang L, Maity T, Li L, Millward SW, Karam JA, Wood CG, Navai N. Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo. Int J Mol Sci. 2021 Mar 11; 22(6). PMID: 33799686; PMCID: PMC8001211.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    44. Umbreit EC, McIntosh AG, Suk-Ouichai C, Karam JA, Wood CG. The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. Indian J Urol. 2021 Jan-Mar; 37(1):13-19. PMID: 33850351; PMCID: PMC8033221.
      Citations:    
    45. Umbreit EC, Siddiqui BA, Hwang MJ, Joon AY, Maity T, Westerman ME, Merriman KW, Alhasson H, Uthup J, Guo T, Moore JA, Ward JF, Karam JA, Wood CG, Pisters LL, Zhang M, Tu SM. Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers (Basel). 2020 Dec 14; 12(12). PMID: 33327406; PMCID: PMC7764868.
      Citations: 8     
    46. Wood CG, Ferguson JE, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY, Milowsky MI, Beckermann KE, Davis NB, Haake SM, Karam JA, Bortone DS, Vincent BG, Powles T, Rathmell WK. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight. 2020 11 19; 5(22). PMID: 33208553; PMCID: PMC7710285.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    47. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16. PMID: 33187886.
      Citations: 1     Fields:    Translation:Humans
    48. Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020 12; 17(12):659-678. PMID: 33051619; PMCID: PMC7551522.
      Citations: 12     Fields:    Translation:HumansCells
    49. Umbreit EC, McIntosh AG, Suk-Ouichai C, Segarra LA, Holland LC, Fellman BM, Williams SB, Thomas AZ, Tu SM, Pettaway CA, Pisters LL, Ward JF, Wood CG, Karam JA. Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer. 2020 11 15; 126(22):4878-4885. PMID: 32940929; PMCID: PMC9379780.
      Citations: 1     Fields:    Translation:Humans
    50. Shapiro DD, Westerman ME, Karam JA, Wood CG. Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease: Have We Finally Answered the Question? Cancer J. 2020 Sep/Oct; 26(5):382-389. PMID: 32947306.
      Citations:    Fields:    Translation:Humans
    51. Westerman ME, Shapiro DD, Tannir NM, Campbell MT, Matin SF, Karam JA, Wood CG. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 2020 12; 126(6):745-753. PMID: 32623821.
      Citations: 3     Fields:    Translation:Humans
    52. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2020 09 15; 26(18):4970-4982. PMID: 32586940; PMCID: PMC7968518.
      Citations: 9     Fields:    Translation:HumansCells
    53. Westerman ME, Shapiro DD, Wood CG, Karam JA. Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma. Urol Clin North Am. 2020 Aug; 47(3):329-343. PMID: 32600535.
      Citations:    Fields:    Translation:Humans
    54. McIntosh AG, Umbreit EC, Holland LC, Gu C, Tannir NM, Matin SF, Karam JA, Culp SH, Wood CG. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020 09 01; 126(17):3950-3960. PMID: 32515845.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    55. Msaouel P, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Karki M, Seervai RNH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM, Malouf GG, Pili? PG, Vokshi BH, Davidson I. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13. PMID: 32359397; PMCID: PMC7288373.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    56. Shapiro DD, Karam JA, Wood CG. EDITORIAL COMMENT. Urology. 2020 02; 136:175. PMID: 32033671.
      Citations:    Fields:    Translation:Humans
    57. Grant SR, Lei X, Hess KR, Smith GL, Matin SF, Wood CG, Nguyen Q, Frank SJ, Anscher MS, Smith BD, Karam JA, Tang C. Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation. Adv Radiat Oncol. 2020 May-Jun; 5(3):495-502. PMID: 32529146; PMCID: PMC7276675.
      Citations: 2     
    58. Dong Y, Dinatale RG, Chen YB, Su X, Mano R, Blum KA, Yao H, Karam JA, Ho TH, Tickoo SK, Russo P, Hsieh JJ, Tannir NM, Hakimi AA, Malouf GG, Flippot R, Comp?rat E, Roupr?t M, Mouawad R, Spano JP, Khayat D. Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Sci Rep. 2020 01 20; 10(1):701. PMID: 31959902; PMCID: PMC6971072.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    59. Yeh HC, Margulis V, Singla N, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li CC, Ke HL, Li WM, Lee HY, Rapoport LM, Lotan Y, Kapur P, Shariat SF, Hsieh JT, Wu WJ. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. Urol Oncol. 2020 05; 38(5):496-505. PMID: 31862213.
      Citations: 2     Fields:    Translation:Humans
    60. Borregales LD, Adibi M, Thomas AZ, Reis RB, Chery LJ, Devine CE, Wang X, Potretzke AM, Potretzke T, Figenshau RS, Bauman TM, Aboshady YI, Abel EJ, Matin SF, Karam JA, Wood CG. Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy. Eur Urol Focus. 2021 03; 7(2):397-403. PMID: 31685445.
      Citations: 4     Fields:    Translation:Humans
    61. Alhalabi O, Karam JA, Tannir NM. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology. Curr Opin Urol. 2019 09; 29(5):521-525. PMID: 31305271.
      Citations: 1     Fields:    Translation:Humans
    62. Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, Gilligan T, Karam JA, Leibovich B, Liauw SL, Masterson TA, Meeks JJ, Pierorazio PM, Sharma R, Sheinfeld J. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 08; 202(2):272-281. PMID: 31059667.
      Citations: 31     Fields:    Translation:Humans
    63. Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell M, Karam JA, Graham PH, Hatia RI, Phan AT, Varghese J, Hassan MM. Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. Int J Cancer. 2020 04 01; 146(7):1836-1840. PMID: 31241762.
      Citations: 4     Fields:    Translation:Humans
    64. Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol. 2020 10; 3(5):687-694. PMID: 31272939; PMCID: PMC6938577.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    65. Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707. PMID: 31231128.
      Citations: 10     Fields:    Translation:HumansCells
    66. Larcher A, Wallis CJD, Bex A, Blute ML, Ficarra V, Karam JA, Van Poppel H, Pal SK, Mejean A. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? Eur Urol Oncol. 2019 07; 2(4):365-378. PMID: 31109902.
      Citations: 14     Fields:    Translation:Humans
    67. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565. PMID: 31067138; PMCID: PMC6599408.
      Citations: 229     Fields:    Translation:HumansCTClinical Trials
    68. Silagy AW, Sanchez A, Manley BJ, Bensalah K, Bex A, Karam JA, Shuch B, Hakimi AA, Ljungberg B. Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management. Eur Urol Focus. 2019 11; 5(6):949-957. PMID: 31040082; PMCID: PMC6815690.
      Citations: 2     Fields:    Translation:Humans
    69. Wang F, Zhang S, Kim TB, Lin YY, Iqbal R, Wang Z, Mohanty V, Sircar K, Karam JA, Wendl MC, Meric-Bernstam F, Weinstein JN, Ding L, Mills GB, Chen K. Integrated transcriptomic-genomic tool Texomer profiles cancer tissues. Nat Methods. 2019 05; 16(5):401-404. PMID: 30988467; PMCID: PMC7337246.
      Citations: 4     Fields:    Translation:HumansCells
    70. Li R, Duplisea JJ, Petros FG, Tu SM, Karam JA, Huynh TT, Ward JF, Gonz?lez GMN. Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. Eur Urol Oncol. 2021 08; 4(4):651-658. PMID: 31412007.
      Citations: 4     Fields:    Translation:Humans
    71. Zacharias NM, Ornelas A, Lee J, Hu J, Davis JS, Uddin N, Pudakalakatti S, Menter DG, Karam JA, Wood CG, Hawk ET, Kopetz S, Vilar E, Bhattacharya PK, Millward SW. Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angew Chem Int Ed Engl. 2019 03 22; 58(13):4179-4183. PMID: 30680862; PMCID: PMC6467058.
      Citations: 4     Fields:    Translation:AnimalsCells
    72. Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2019 Nov; 37(11):2419-2427. PMID: 30759271.
      Citations: 2     Fields:    Translation:Humans
    73. Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G, Malouf GG, Sgambato A. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 2019 02 11; 35(2):204-220.e9. PMID: 30753823; PMCID: PMC7876656.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    74. Patel HD, Karam JA, Allaf ME. Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy. J Clin Oncol. 2018 10 29; JCO2018790246. PMID: 30372387.
      Citations: 6     Fields:    
    75. Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T, Bex A. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol. 2019 01; 75(1):111-128. PMID: 30467042.
      Citations: 36     Fields:    Translation:Humans
    76. Sekino Y, Sakamoto N, Goto K, Honma R, Shigematsu Y, Quoc TP, Sentani K, Oue N, Teishima J, Kawakami F, Karam JA, Sircar K, Matsubara A, Yasui W. Uc.416?+?A promotes epithelial-to-mesenchymal transition through miR-153 in renal cell carcinoma. BMC Cancer. 2018 Oct 04; 18(1):952. PMID: 30286729; PMCID: PMC6172711.
      Citations: 7     Fields:    Translation:HumansCells
    77. Yu KJ, Keskin SK, Meissner MA, Petros FG, Wang X, Borregales LD, Gu C, Tamboli P, Matin SF, Wood CG, Karam JA. Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. Cancer. 2018 10 15; 124(20):4023-4031. PMID: 30276798.
      Citations: 10     Fields:    Translation:Humans
    78. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer. 2019 02; 17(1):1-6. PMID: 30287223; PMCID: PMC6348017.
      Citations: 13     Fields:    Translation:Humans
    79. Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus. 2020 01 15; 6(1):104-111. PMID: 30206003; PMCID: PMC7771285.
      Citations: 6     Fields:    Translation:HumansCells
    80. Zhang J, Ye Y, Chang DW, Lin SH, Huang M, Tannir NM, Matin S, Karam JA, Wood CG, Chen ZN, Wu X. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. Am J Pathol. 2018 11; 188(11):2487-2496. PMID: 30201497; PMCID: PMC6207099.
      Citations: 16     Fields:    Translation:Humans
    81. Petros FG, Venkatesan AM, Kaya D, Ng CS, Fellman BM, Karam JA, Wood CG, Matin SF. Conditional survival of patients with small renal masses undergoing active surveillance. BJU Int. 2019 03; 123(3):447-455. PMID: 30007044.
      Citations: 2     Fields:    Translation:Humans
    82. Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Matin S, Sjoberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A, Ljungberg B. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World J Urol. 2018 Dec; 36(12):1973-1980. PMID: 30069581.
      Citations: 5     Fields:    Translation:Humans
    83. Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez C, Roman-Gonzalez A. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg. 2018 07; 268(1):172-178. PMID: 28257320.
      Citations: 23     Fields:    Translation:Humans
    84. Sun M, Meyer CP, Karam JA, de Velasco G, Chang SL, Pal SK, Trinh QD, Choueiri TK. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. Eur J Surg Oncol. 2018 09; 44(9):1439-1445. PMID: 29935840.
      Citations: 7     Fields:    Translation:Humans
    85. Shu X, Gu J, Huang M, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X, Ye Y. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis. 2018 05 28; 39(6):752-757. PMID: 29635281; PMCID: PMC5972595.
      Citations: 8     Fields:    Translation:Humans
    86. Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034. PMID: 29804202; PMCID: PMC6261784.
      Citations: 1     Fields:    Translation:Humans
    87. Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urol Oncol. 2018 Jul; 36(7):343.e1-343.e8. PMID: 29748098.
      Citations: 2     Fields:    Translation:Humans
    88. Meissner MA, McCormick BZ, Karam JA, Wood CG. Adjuvant therapy for advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2018 07; 18(7):663-671. PMID: 29707987.
      Citations: 6     Fields:    Translation:Humans
    89. Petros FG, Keskin SK, Yu KJ, Li R, Metcalfe MJ, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG. Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology. 2018 Jun; 116:114-119. PMID: 29578041.
      Citations: 7     Fields:    Translation:Humans
    90. Karam JA. Editorial Comment. J Urol. 2018 06; 199(6):1432. PMID: 29555540.
      Citations:    Fields:    Translation:Humans
    91. Bhindi B, Wallis CJD, Boorjian SA, Thompson RH, Farrell A, Kim SP, Karam JA, Capitanio U, Golijanin D, Leibovich BC, Gershman B. The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. BJU Int. 2018 05; 121(5):684-698. PMID: 29319926.
      Citations: 19     Fields:    Translation:Humans
    92. Hutchinson R, Rew C, Chen G, Woldu S, Krabbe LM, Meissner M, Sheth K, Singla N, Shakir N, Master VA, Karam JA, Matin SF, Borregales LD, Wood C, Masterson T, Thompson RH, Boorjian SA, Leibovich BC, Abel EJ, Bagrodia A, Margulis V. The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology. 2018 May; 115:119-124. PMID: 29499258.
      Citations: 7     Fields:    Translation:HumansCells
    93. Petros FG, Metcalfe MJ, Yu KJ, Keskin SK, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. World J Urol. 2018 Jul; 36(7):1093-1101. PMID: 29488096.
      Citations: 9     Fields:    Translation:Humans
    94. McCormick B, Meissner MA, Karam JA, Wood CG. Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer. 2017 Nov 27; 1(2):115-121. PMID: 30334013; PMCID: PMC6179118.
      Citations:    
    95. Chipollini J, Abel EJ, Peyton CC, Boulware DC, Karam JA, Margulis V, Master VA, Zargar-Shoshtari K, Matin SF, Sexton WJ, Raman JD, Wood CG, Spiess PE. Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clin Genitourin Cancer. 2018 04; 16(2):e443-e450. PMID: 29113770; PMCID: PMC7771342.
      Citations: 3     Fields:    Translation:Humans
    96. Han G, Zhao W, Song X, Kwok-Shing Ng P, Karam JA, Jonasch E, Mills GB, Zhao Z, Ding Z, Jia P. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. BMC Genomics. 2017 Oct 03; 18(Suppl 6):678. PMID: 28984208; PMCID: PMC5629613.
      Citations: 15     Fields:    Translation:HumansPHPublic Health
    97. Karam JA, Wood CG. Editorial Comment. J Urol. 2018 01; 199(1):52. PMID: 28945990.
      Citations:    Fields:    Translation:Humans
    98. Wood EL, Adibi M, Qiao W, Brandt J, Zhang M, Tamboli P, Matin SF, Wood CG, Karam JA. Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. J Urol. 2018 02; 199(2):393-400. PMID: 28941919.
      Citations: 10     Fields:    Translation:Humans
    99. Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831. PMID: 28832979; PMCID: PMC5731248.
      Citations: 36     Fields:    Translation:HumansCells
    100. Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953. PMID: 28731777; PMCID: PMC5915259.
      Citations: 9     Fields:    Translation:Humans
    101. Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696. PMID: 28710314; PMCID: PMC5683086.
      Citations: 26     Fields:    Translation:Humans
    102. Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, Guo CC, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Bachmann A, De Marzo AM, Robinson BD, Margulis V. Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. J Urol. 2017 12; 198(6):1269-1277. PMID: 28709887.
      Citations: 2     Fields:    Translation:Humans
    103. Borregales LD, Fellman B, Urbauer DL, Garg N, Parker N, Katz MHG, Wood CG, Karam JA, Ch?ry L. The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. Urology. 2017 10; 108:114-121. PMID: 28705573; PMCID: PMC5790178.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    104. D'Andrea D, Moschini M, Foerster B, Abufaraj M, Margulis V, Karam J, Lotan Y, Raman J, Mathieu R, Karakiewicz PI, Briganti A, Haitel A, Shariat SF, Roupr?t M. Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. Eur Urol Focus. 2019 01; 5(1):97-103. PMID: 28753840.
      Citations: 2     Fields:    Translation:HumansCells
    105. Krabbe LM, Heitplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V, Xylinas E. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2017 12; 198(6):1253-1262. PMID: 28668287.
      Citations: 25     Fields:    Translation:Humans
    106. Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. Eur Urol. 2018 01; 73(1):71-78. PMID: 28592388.
      Citations: 25     Fields:    Translation:HumansCells
    107. Gu J, Herrera LA, Tannir NM, Zhang S, Matin S, Karam JA, Wood CG, Wu X, Mendoza-P?rez J. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer. 2017 Sep 15; 123(18):3617-3627. PMID: 28543182; PMCID: PMC5589484.
      Citations: 13     Fields:    Translation:HumansCells
    108. Abel EJ, Masterson TA, Karam JA, Master VA, Margulis V, Hutchinson R, Lorentz CA, Bloom E, Bauman TM, Wood CG, Blute ML. Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. J Urol. 2017 10; 198(4):810-816. PMID: 28411071.
      Citations: 4     Fields:    Translation:Humans
    109. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537. PMID: 28411072; PMCID: PMC5597336.
      Citations: 20     Fields:    Translation:Humans
    110. Meyer CP, Sun M, Karam JA, Leow JJ, de Velasco G, Pal SK, Chang SL, Trinh QD, Choueiri TK. Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment. Eur Urol. 2017 08; 72(2):171-174. PMID: 28359734.
      Citations: 9     Fields:    Translation:Humans
    111. Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar-Shoshtari K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 08; 198(2):281-288. PMID: 28268170.
      Citations: 13     Fields:    Translation:Humans
    112. Meissner MA, Karam JA. Nephrometry scoring systems: valuable research tools, but can they be applied in daily clinical practice? BJU Int. 2017 03; 119(3):364-365. PMID: 28211238.
      Citations:    Fields:    Translation:Humans
    113. Karam JA, Parikh RY, Nayak D, Gangaraju VK, Rosenkranz D. Co-chaperone Hsp70/Hsp90-organizing protein (Hop) is required for transposon silencing and Piwi-interacting RNA (piRNA) biogenesis. J Biol Chem. 2017 04 14; 292(15):6039-6046. PMID: 28193840; PMCID: PMC5391737.
      Citations: 13     Fields:    Translation:AnimalsCells
    114. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370. PMID: 28216278.
      Citations: 8     Fields:    Translation:Humans
    115. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289. PMID: 27861143; PMCID: PMC5349913.
      Citations: 14     Fields:    Translation:Humans
    116. Shah AY, Karam JA, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM, Malouf GG. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792. PMID: 27860149; PMCID: PMC6857178.
      Citations: 22     Fields:    Translation:Humans
    117. Pal SK, Karam JA, Bergerot P, Agarwal N. Developing a Clear Path Forward for Non-Clear-Cell Renal Carcinoma. J Clin Oncol. 2016 11 10; 34(32):3825-3826. PMID: 27601540.
      Citations: 1     Fields:    Translation:Humans
    118. Abufaraj M, Moschini M, Soria F, Gust K, Mathieu R, Margulis V, Karam JA, Wood CG, Briganti A, Bensalah K, Haitel A, Shariat SF, ?zsoy M, Roupr?t M. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2017 Jul; 35(7):1073-1080. PMID: 27830374; PMCID: PMC5486535.
      Citations: 6     Fields:    Translation:Humans
    119. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682. PMID: 27789196; PMCID: PMC5143183.
      Citations: 308     Fields:    Translation:HumansCTClinical Trials
    120. Kawakami F, Rao P, Tamboli P, Wood CG, Karam JA. Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial. J Urol. 2017 03; 197(3 Pt 1):559-565. PMID: 27678298.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    121. Pal SK, Karam JA, Chennamsetty A, Jones JO. Biomarkers in Genitourinary Cancers: Blazing the Path Forward. Eur Urol. 2017 02; 71(2):247-248. PMID: 27639532.
      Citations: 1     Fields:    Translation:Humans
    122. Chery LJ, Karam JA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma. Clin Adv Hematol Oncol. 2016 Sep; 14(9):696-703. PMID: 27673288.
      Citations: 1     Fields:    Translation:Humans
    123. Biebighauser KC, Gao J, Rao P, Landon G, Pagliaro L, Dinney CPN, Karam J, Navai N. Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation. Asian J Urol. 2017 Apr; 4(2):124-127. PMID: 29264217; PMCID: PMC5717982.
      Citations:    
    124. Haitel A, Karam JA, Wood CG, Margulis V, Karakiewicz PI, Briganti A, Raman JD, Kammerer-Jacquet SF, Mathieu R, Bensalah K, Lotan Y, Soria F, Moschini M, Wirth GJ, Roupr?t M, ?zsoy M, Remzi M, Gust KM, Shariat SF. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World J Urol. 2017 Feb; 35(2):251-259. PMID: 27272502.
      Citations: 9     Fields:    Translation:Humans
    125. Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Karam JA, Tamboli P, Wood CG, Jelinek J, Tannir NM, Malouf GG, Raynal NJ, Allanick F, Mouawad R, Spano JP, Khayat D. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res. 2016 Dec 15; 22(24):6236-6246. PMID: 27256309; PMCID: PMC5135666.
      Citations: 22     Fields:    Translation:HumansCells
    126. Vartolomei MD, Mathieu R, Margulis V, Karam JA, Lucca I, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Rioux-Leclercq N, Haitel A, Bensalah K, Rink M, Briganti A, Shariat SF, Roupr?t M, Mbeutcha A, Xylinas E. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World J Urol. 2017 Jan; 35(1):121-130. PMID: 27209168; PMCID: PMC5233730.
      Citations: 11     Fields:    Translation:HumansCells
    127. Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, Shariat S, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclerq N, Bolenz C, Roscigno M, Krabbe LM, Kapur P, Lotan Y, Margulis V, DeGraff DJ. Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology. 2016 Aug; 94:314.e1-7. PMID: 27215483.
      Citations: 8     Fields:    Translation:Humans
    128. Haitel A, Margulis V, Karam JA, Karakiewicz PI, Wood CG, Weizer AZ, Raman JD, Rioux-Leclercq N, Jacquet-Kammerer S, Bensalah K, Lotan Y, Bachmann A, Rink M, Briganti A, Favaretto RL, Bahadori A, Mathieu R, Grubm?ller B, Roupr?t M, Seitz C, Cunha IW, Zequi SC, Remzi M, Shariat SF. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2017 Jan; 35(1):113-120. PMID: 27129576; PMCID: PMC5233747.
      Citations: 8     Fields:    Translation:Humans
    129. Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84. PMID: 27036304; PMCID: PMC5014677.
      Citations: 12     Fields:    Translation:Humans
    130. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43. PMID: 27018785; PMCID: PMC5071733.
      Citations: 17     Fields:    Translation:HumansCells
    131. Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA, Malouf GG, Khayat D. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016 08; 70(2):348-57. PMID: 26895810.
      Citations: 51     Fields:    Translation:Humans
    132. Thomas AZ, Blute ML, Seitz C, Habra MA, Karam JA. Management of the Incidental Adrenal Mass. Eur Urol Focus. 2016 Feb; 1(3):223-230. PMID: 28723391.
      Citations: 6     Fields:    
    133. Huang H, Tamboli P, Karam JA, Vikram R, Zhang M. Secondary malignancies diagnosed using kidney needle core biopsies: a clinical and pathological study of 75 cases. Hum Pathol. 2016 06; 52:55-60. PMID: 26980018.
      Citations: 5     Fields:    Translation:Humans
    134. Matin SF, Melquist J, Karam JA. Author reply. Urology. 2016 Jan; 87:222-3. PMID: 27243090.
      Citations:    Fields:    Translation:Humans
    135. Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26. PMID: 26707613; PMCID: PMC4835261.
      Citations: 4     Fields:    Translation:Humans
    136. Margulis V, Karam JA, Wood CG, Haitel A, Xylinas E, Kluth L, Karakiewicz PI, Rink M, Weizer AZ, Raman JD, Rioux-Leclecq N, Bolenz C, Bensalah K, Lotan Y, Remzi M, Mbeutcha A, Lucca I, de Martino M, Mathieu R, Roupr?t M, Briganti A, Rieken M, Seitz C, Shariat SF, Klatte T. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World J Urol. 2016 Aug; 34(8):1155-61. PMID: 26658888.
      Citations: 4     Fields:    Translation:Humans
    137. Gu J, Tannir NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG, Wu X, Mendoza-P?rez J, Herrera LA. Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. Clin Cancer Res. 2016 Apr 15; 22(8):2074-82. PMID: 26655847; PMCID: PMC4834236.
      Citations: 12     Fields:    Translation:HumansCells
    138. Ho TH, Choueiri TK, Wang K, Karam JA, Chalmers Z, Frampton G, Elvin JA, Johnson A, Liu X, Lin Y, Joseph RW, Stanton ML, Miller VA, Stephens PJ, Ross JS, Ali SM, Pal SK. Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. Eur Urol Focus. 2016 Jun; 2(2):204-209. PMID: 28723536.
      Citations: 20     Fields:    
    139. Pal SK, Choueiri TK, Karam JA, Heng DY. Metastatic renal cell carcinoma: Contending with a sea change in therapy. Urol Oncol. 2015 Dec; 33(12):507-8. PMID: 26584741.
      Citations: 3     Fields:    Translation:Humans
    140. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74. PMID: 26626617; PMCID: PMC4879109.
      Citations: 100     Fields:    Translation:HumansCTClinical Trials
    141. Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2016 Apr; 8(2):130-41. PMID: 27034725; PMCID: PMC4772353.
      Citations: 26     
    142. Lotan Y, Karam JA, Shariat SF, Gupta A, Bensalah K, Margulis V, Roupret M. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. Urol Oncol. 2016 Apr; 34(4):167.e9-16. PMID: 26602092.
      Citations: 9     Fields:    Translation:HumansPHPublic Health
    143. Karam JA, Matin SF. Positive Margins after Radical Nephrectomy with Venous Thrombectomy: Controversies and Treatment Options. J Urol. 2016 Feb; 195(2):241-2. PMID: 26585683.
      Citations:    Fields:    Translation:Humans
    144. Melkonian SC, Daniel CR, Ye Y, Tannir NM, Karam JA, Matin SF, Wood CG, Wu X. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer. 2016 Jan 01; 122(1):108-15. PMID: 26551148; PMCID: PMC5016565.
      Citations: 13     Fields:    Translation:Humans
    145. Adibi M, Thomas AZ, Borregales LD, Matin SF, Wood CG, Karam JA. Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol. 2015 Dec; 33(12):528-37. PMID: 26546481.
      Citations: 9     Fields:    Translation:Humans
    146. Melquist JJ, Redrow G, Delacroix S, Park A, Faria EE, Karam JA, Matin SF. Comparison of Single-docking Robotic-assisted and Traditional Laparoscopy for Retroperitoneal Lymph Node Dissection During Nephroureterectomy With Bladder Cuff Excision for Upper-tract Urothelial Carcinoma. Urology. 2016 Jan; 87:216-23. PMID: 26494291.
      Citations: 10     Fields:    Translation:Humans
    147. Abel EJ, Margulis V, Bauman TM, Karam JA, Christensen WP, Krabbe LM, Haddad A, Golla V, Wood CG. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. BJU Int. 2016 Jun; 117(6B):E87-94. PMID: 26305276.
      Citations: 14     Fields:    Translation:Humans
    148. Adibi M, Kenney PA, Thomas AZ, Borregales LD, Wang X, Devine CE, Karam JA, Wood CG, Nogueras-Gonz?lez GM. Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. Eur Urol. 2016 Feb; 69(2):352-60. PMID: 26382085.
      Citations: 4     Fields:    Translation:Humans
    149. Thomas AZ, Adibi M, Borregales LD, Wood CG, Karam JA. Role of metastasectomy in metastatic renal cell carcinoma. Curr Opin Urol. 2015 Sep; 25(5):381-9. PMID: 26125508.
      Citations: 6     Fields:    Translation:Humans
    150. Lee BM, Singh Ghotra V, Karam JA, Hernandez M, Pratt G, Cata JP. Regional anesthesia/analgesia and the risk of cancer recurrence and mortality after prostatectomy: a meta-analysis. Pain Manag. 2015 Sep; 5(5):387-95. PMID: 26250850; PMCID: PMC5561907.
      Citations: 10     Fields:    Translation:Humans
    151. Bex A, Powles T, Karam JA. Role of targeted therapy in combination with surgery in renal cell carcinoma. Int J Urol. 2016 Jan; 23(1):5-12. PMID: 26238981.
      Citations: 8     Fields:    Translation:Humans
    152. Mathieu R, Klatte T, Margulis V, Karam JA, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Rink M, Kluth LA, Scherr DS, Robinson BD, Shariat SF, Roupr?t M. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol. 2015 Nov; 33(11):495.e15-22. PMID: 26228160.
      Citations: 7     Fields:    Translation:Humans
    153. Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Oct; 1(4):212-24. PMID: 27499906; PMCID: PMC4939892.
      Citations: 5     Fields:    
    154. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5. PMID: 26032863; PMCID: PMC4666814.
      Citations: 26     Fields:    Translation:Humans
    155. Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, Wood CG, Karam JA. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int. 2016 May; 117(5):775-82. PMID: 26053895; PMCID: PMC4670601.
      Citations: 21     Fields:    Translation:Humans
    156. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76. PMID: 26059275; PMCID: PMC4808616.
      Citations: 17     Fields:    Translation:Humans
    157. Pal SK, Choueiri TK, Wang K, Khaira D, Karam JA, Van Allen E, Palma NA, Stein MN, Johnson A, Squillace R, Elvin JA, Chmielecki J, Yelensky R, Yakirevich E, Lipson D, Lin DI, Miller VA, Stephens PJ, Ali SM, Ross JS. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. Eur Urol. 2016 09; 70(3):516-21. PMID: 26149668.
      Citations: 26     Fields:    Translation:HumansCells
    158. Karam JA, Devine CE, Fellman BM, Urbauer DL, Abel EJ, Allaf ME, Bex A, Lane BR, Thompson RH, Wood CG. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial. BJU Int. 2016 Apr; 117(4):629-35. PMID: 26033220; PMCID: PMC4666818.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    159. Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35. PMID: 26111976; PMCID: PMC4556533.
      Citations: 12     Fields:    Translation:HumansCells
    160. Thomas AZ, Adibi M, Borregales LD, Karam JA, Wood CG. Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol. 2015 Jun; 4(3):301-9. PMID: 26815334; PMCID: PMC4708236.
      Citations: 2     
    161. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29. PMID: 26014097; PMCID: PMC4561186.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    162. Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23. PMID: 26004164; PMCID: PMC4584175.
      Citations: 14     Fields:    Translation:Humans
    163. Gayed BA, Gillen J, Christie A, Xie XJ, Yan J, Karam JA, Raj G, Sagalowsky AI, Lotan Y, Margulis V, Brugarolas J, Pe?a-Llopis S. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. BMC Urol. 2015 Apr 03; 15:24. PMID: 25885592; PMCID: PMC4411704.
      Citations: 2     Fields:    Translation:Humans
    164. Kenney PA, Vikram R, Prasad SR, Tamboli P, Matin SF, Wood CG, Karam JA. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int. 2015 Jul; 116(1):85-92. PMID: 25395040.
      Citations: 20     Fields:    Translation:Humans
    165. Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22. PMID: 25758610; PMCID: PMC4666307.
      Citations: 13     Fields:    Translation:Humans
    166. Shah AY, Karam JA, Lim ZD, Ng CS, Tannir NM. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy? Urol Case Rep. 2015 Mar 01; 3(2):18-20. PMID: 26120560; PMCID: PMC4477704.
      Citations: 2     
    167. Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9. PMID: 25700975; PMCID: PMC4664068.
      Citations: 20     Fields:    Translation:Humans
    168. Karam JA, Wood CG, Compton ZR, Rao P, Vikram R, Ahrar K, Matin SF. Salvage surgery after energy ablation for renal masses. BJU Int. 2015 Jan; 115(1):74-80. PMID: 24656119.
      Citations: 7     Fields:    Translation:Humans
    169. Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ. Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Med Res Methodol. 2014 Dec 22; 14:138. PMID: 25532962; PMCID: PMC4292824.
      Citations: 8     Fields:    Translation:HumansCells
    170. Karam JA, Huang RC, Abraham JA, Parvizi J. Total joint arthroplasty in cancer patients. J Arthroplasty. 2015 May; 30(5):758-61. PMID: 25583683.
      Citations: 7     Fields:    Translation:Humans
    171. Koh MY, Nguyen V, Lemos R, Darnay BG, Kiriakova G, Abdelmelek M, Ho TH, Karam J, Monzon FA, Jonasch E, Powis G. Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. Cancer Res. 2015 Jan 15; 75(2):316-29. PMID: 25421578; PMCID: PMC4297521.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    172. Krabbe LM, Bagrodia A, Haddad AQ, Kapur P, Khalil D, Hynan LS, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V. Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. J Urol. 2015 May; 193(5):1486-93. PMID: 25451830.
      Citations: 15     Fields:    Translation:Humans
    173. Adibi M, Karam JA, Wood CG. Reporting geographic and temporal trends in renal cell carcinoma: why is this important? Eur Urol. 2015 Mar; 67(3):531-2. PMID: 25454608.
      Citations: 3     Fields:    Translation:Humans
    174. Babaian KN, Kim DY, Kenney PA, Wood CG, Wong J, Sanchez C, Fang JE, Gerber JA, Didic A, Wahab A, Golla V, Torres C, Tamboli P, Qiao W, Matin SF, Wood CG, Karam JA. Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection. J Urol. 2015 Apr; 193(4):1101-7. PMID: 25390078.
      Citations: 17     Fields:    Translation:Humans
    175. Bagrodia A, Krabbe LM, Gayed BA, Kapur P, Bernstein I, Xie XJ, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclerq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. Urology. 2014 Nov; 84(5):1134-40. PMID: 25443916.
      Citations: 10     Fields:    Translation:Humans
    176. Pal SK, He M, Tong T, Wu H, Liu X, Lau C, Wang JH, Warden C, Wu X, Signoretti S, Choueiri TK, Karam JA, Jones JO. RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res. 2015 Jan; 13(1):130-7. PMID: 25183163; PMCID: PMC4608366.
      Citations: 24     Fields:    Translation:HumansCells
    177. Karmali RJ, Suami H, Wood CG, Karam JA. Lymphatic drainage in renal cell carcinoma: back to the basics. BJU Int. 2014 Dec; 114(6):806-17. PMID: 24841690.
      Citations: 15     Fields:    Translation:Humans
    178. Kim DY, Karam JA. For the RECORD, we should SWITCH our treatment AXIS before the SUNRISES and TARGET the BEST treatments before INTORSECTing with a GOLD METEOR: a tale of sequences and combinations. Eur Urol. 2015 Jan; 67(1):111-113. PMID: 24953406.
      Citations: 1     Fields:    Translation:Humans
    179. Kim DY, Karam JA. Editorial Comment to Growing teratoma syndrome: clinical and radiographic characteristics. Int J Urol. 2014 Sep; 21(9):909. PMID: 24796961.
      Citations:    Fields:    Translation:Humans
    180. Karam JA, Zmistowski B, Restrepo C, Hozack WJ, Parvizi J. Fewer postoperative fevers: an unexpected benefit of multimodal pain management? Clin Orthop Relat Res. 2014 May; 472(5):1489-95. PMID: 24615425; PMCID: PMC3971226.
      Citations: 2     Fields:    Translation:Humans
    181. Kim DY, Karam JA, Wood CG. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol. 2014 Jun; 32(3):631-42. PMID: 24744223.
      Citations: 17     Fields:    Translation:Humans
    182. Culp SH, Karam JA, Wood CG. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urol Oncol. 2014 Jul; 32(5):561-8. PMID: 24709415.
      Citations: 11     Fields:    Translation:Humans
    183. Abel EJ, Carrasco A, Karam J, Tamboli P, Delacroix S, Vaporciyan AA, Wood CG. Positive vascular wall margins have minimal impact on cancer outcomes in patients with non-metastatic renal cell carcinoma (RCC) with tumour thrombus. BJU Int. 2014 Nov; 114(5):667-73. PMID: 24128265.
      Citations: 7     Fields:    Translation:Humans
    184. Babaian KN, Merrill MM, Matin S, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42. PMID: 24518767; PMCID: PMC4502598.
      Citations: 3     Fields:    Translation:Humans
    185. Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014 Nov; 66(5):874-80. PMID: 24560330; PMCID: PMC4396847.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    186. Tokarski AT, Karam JA, Zmistowski B, Deirmengian CA, Deirmengian GK. Clostridium difficile is common in patients with postoperative diarrhea after hip and knee arthroplasty. J Arthroplasty. 2014 Jun; 29(6):1110-3. PMID: 24530206.
      Citations: 1     Fields:    Translation:HumansCells
    187. Kim DY, Wood CG, Karam JA. Treating the two extremes in renal cell carcinoma: management of small renal masses and cytoreductive nephrectomy in metastatic disease. Am Soc Clin Oncol Educ Book. 2014; e214-21. PMID: 24857105.
      Citations: 3     Fields:    Translation:Humans
    188. Lee DJ, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, Shariat SF, Robinson BD, Margulis V, Xylinas E. Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. Eur Urol. 2014 Aug; 66(2):379-85. PMID: 24388440.
      Citations: 12     Fields:    Translation:Humans
    189. Zmistowski B, Karam JA, Durinka JB, Casper DS, Parvizi J. Periprosthetic joint infection increases the risk of one-year mortality. J Bone Joint Surg Am. 2013 Dec 18; 95(24):2177-84. PMID: 24352771.
      Citations: 131     Fields:    Translation:Humans
    190. Ngo TC, Wood CG, Karam JA. Biomarkers of renal cell carcinoma. Urol Oncol. 2014 Apr; 32(3):243-51. PMID: 24239464.
      Citations: 15     Fields:    Translation:Humans
    191. Morgan JA, Tsiouris A, Nemeh HW, Hodari A, Karam J, Brewer RJ, Paone G. Impact of concomitant cardiac procedures performed during implantation of long-term left ventricular assist devices. J Heart Lung Transplant. 2013 Dec; 32(12):1255-61. PMID: 24135274.
      Citations: 8     Fields:    Translation:Humans
    192. Karam JA, Bloomfield MR, DiIorio TM, Irizarry AM, Sharkey PF. Evaluation of the efficacy and safety of tranexamic acid for reducing blood loss in bilateral total knee arthroplasty. J Arthroplasty. 2014 Mar; 29(3):501-3. PMID: 24051240.
      Citations: 18     Fields:    Translation:Humans
    193. Laguna MP. Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. J Urol. 2013 Nov; 190(5):1710. PMID: 24120769.
      Citations:    Fields:    Translation:Humans
    194. Karam J, Shepard A, Rubinfeld I. Predictors of operative mortality following major lower extremity amputations using the National Surgical Quality Improvement Program public use data. J Vasc Surg. 2013 Nov; 58(5):1276-82. PMID: 23830311.
      Citations: 15     Fields:    Translation:Humans
    195. Faria EF, Caputo PA, Wood CG, Karam JA, Matin SF, Nogueras-Gonz?lez GM. Robotic partial nephrectomy shortens warm ischemia time, reducing suturing time kinetics even for an experienced laparoscopic surgeon: a comparative analysis. World J Urol. 2014 Feb; 32(1):265-71. PMID: 23783881; PMCID: PMC3874425.
      Citations: 8     Fields:    Translation:Humans
    196. Karam J, Tsiouris A, Shepard A, Velanovich V, Rubinfeld I. Simplified frailty index to predict adverse outcomes and mortality in vascular surgery patients. Ann Vasc Surg. 2013 Oct; 27(7):904-8. PMID: 23711971.
      Citations: 61     Fields:    Translation:Humans
    197. Karam JA, Wood CG. Words of wisdom: re: prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Eur Urol. 2013 Apr; 63(4):769. PMID: 23438394.
      Citations:    Fields:    
    198. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. 2013 May; 111(6):997-1005. PMID: 23510233; PMCID: PMC3637414.
      Citations: 5     Fields:    Translation:Humans
    199. Tsiouris A, Borgi J, Karam J, Nemeh HW, Paone G, Brewer RJ, Morgan JA. Ischemic versus nonischemic dilated cardiomyopathy: the implications of heart failure etiology on left ventricular assist device outcomes. ASAIO J. 2013 Mar-Apr; 59(2):130-5. PMID: 23438774.
      Citations: 3     Fields:    Translation:Humans
    200. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol. 2013 Jun; 63(6):1122-7. PMID: 23419322; PMCID: PMC3866912.
      Citations: 21     Fields:    Translation:Humans
    201. Karam JA, Tokarski AT, Ciccotti M, Austin MS, Deirmengian GK. Revision total hip arthroplasty in younger patients: indications, reasons for failure, and survivorship. Phys Sportsmed. 2012 Nov; 40(4):96-101. PMID: 23306419.
      Citations: 3     Fields:    Translation:Humans
    202. Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, Margulis V, Patard JJ, Escudier B, Linehan WM. Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol. 2013 Feb; 63(2):244-51. PMID: 23063455; PMCID: PMC3709870.
      Citations: 37     Fields:    Translation:HumansCells
    203. Kenney PA, Karam JA. Percutaneous cryoablation of solitary sporadic renal cell carcinomas. BJU Int. 2012 Dec; 110(11 Pt B):E532. PMID: 22583351.
      Citations:    Fields:    Translation:Humans
    204. Karam JA, Wood CG. The effects of temporary ischemia in partial nephrectomy on renal functional outcomes: how can effects best be estimated, and can they be mitigated? Eur Urol. 2012 Jul; 62(1):136-8; discussion 138-9. PMID: 22410575.
      Citations:    Fields:    Translation:Humans
    205. Kenney PA, Karam JA. Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis. BJU Int. 2012 Sep; 110(6 Pt B):E191. PMID: 22321381.
      Citations:    Fields:    Translation:Humans
    206. Karam JA, Wood CG. Management of small renal masses: watch, cut, freeze, or fry? Eur Urol. 2012 May; 61(5):905-6; discussion 906-7. PMID: 22310973.
      Citations: 2     Fields:    Translation:Humans
    207. Kenney PA, Karam JA. Editorial comment. J Urol. 2012 Feb; 187(2):492. PMID: 22177914.
      Citations:    Fields:    Translation:Humans
    208. Karam JA, Wood CG. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Hematol Oncol Clin North Am. 2011 Aug; 25(4):753-64. PMID: 21763966.
      Citations: 6     Fields:    Translation:Humans
    209. Abel EJ, Karam JA, Carrasco A, Matin SF. Laparoscopic adrenalectomy for metachronous metastases after ipsilateral nephrectomy for renal-cell carcinoma. J Endourol. 2011 Aug; 25(8):1323-7. PMID: 21774667; PMCID: PMC3148128.
      Citations: 7     Fields:    Translation:Humans
    210. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int. 2011 Oct; 108(7):1119-23. PMID: 21426474.
      Citations: 21     Fields:    Translation:HumansPHPublic Health
    211. Karam JA. Editorial comment: Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2. BJU Int. 2011 Aug; 108(4):537-8. PMID: 21371243.
      Citations:    Fields:    Translation:Humans
    212. Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011 Jun; 59(6):912-8. PMID: 21367518.
      Citations: 66     Fields:    Translation:Humans
    213. Karam JA, Wood CG. The dark side of targeted therapy. Eur Urol. 2011 Apr; 59(4):541-2. PMID: 21295398.
      Citations: 1     Fields:    Translation:Humans
    214. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011 Feb; 185(2):439-44. PMID: 21167518; PMCID: PMC4668716.
      Citations: 41     Fields:    Translation:Humans
    215. Karam JA, Ahrar K, Matin SF. Ablation of kidney tumors. Surg Oncol Clin N Am. 2011 Apr; 20(2):341-53, viii. PMID: 21377587.
      Citations: 1     Fields:    Translation:Humans
    216. Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp SH, Wood CG. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol. 2011 Apr; 59(4):619-28. PMID: 21167632.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    217. Karam JA, Huang S, Fan J, Stanfield J, Schultz RA, Pong RC, Sun X, Mason RP, Xie XJ, Niu G, Chen X, Frenkel EP, Sagalowsky AI, Hsieh JT. Upregulation of TRAG3 gene in urothelial carcinoma of the bladder. Int J Cancer. 2011 Jun 15; 128(12):2823-32. PMID: 20734393; PMCID: PMC3082622.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    218. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol. 2010 Nov; 184(5):1882-7. PMID: 20846689; PMCID: PMC4777338.
      Citations: 2     Fields:    Translation:Humans
    219. Karam JA, Kamat AM. Optimal timing of chemotherapy and cystectomy. F1000 Med Rep. 2010 Jun 23; 2. PMID: 20948836; PMCID: PMC2950042.
      Citations: 1     
    220. Karam JA, Wood CG. Editorial comment. J Urol. 2010 Mar; 183(3):870; discussion 870. PMID: 20083268.
      Citations:    Fields:    Translation:Humans
    221. Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Sagalowsky AI, Lotan Y, M?ller SC. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 2009 Nov 15; 15(22):7012-9. PMID: 19903782.
      Citations: 23     Fields:    Translation:Humans
    222. Karam JA, Raj GV. Growing teratoma syndrome. Urology. 2009 Oct; 74(4):783-4. PMID: 19647298.
      Citations: 3     Fields:    Translation:Humans
    223. Khreiss M, Karam J, Musallam KM, Al Harakeh AB, Nasr VG, Abi Saad GS. Distinctive presentation of a diaphragmatic hernia 15 years after a traumatic insult. Ann Thorac Surg. 2009 Aug; 88(2):651-3. PMID: 19632432.
      Citations: 3     Fields:    Translation:Humans
    224. Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Karam JA, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Cote RJ, M?ller SC. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009 Sep; 182(3):907-13. PMID: 19616250.
      Citations: 15     Fields:    Translation:Humans
    225. Decker DB, Karam JA, Wilcox DT. Pediatric hemorrhagic cystitis. J Pediatr Urol. 2009 Aug; 5(4):254-64. PMID: 19303365.
      Citations: 18     Fields:    Translation:HumansCells
    226. Shariat SF, Karam JA, Karakiewicz PI. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81. Eur Urol. 2009 Jan; 55(1):250-2. PMID: 20050019.
      Citations:    Fields:    
    227. Karam JA, Shariat SF, Hsieh JT, Knowles MA. Genomics: a preview of genomic medicine. BJU Int. 2008 Nov; 102(9 Pt B):1221-7. PMID: 19035885.
      Citations: 2     Fields:    Translation:Humans
    228. Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res. 2008 Jun 15; 14(12):3785-91. PMID: 18559597.
      Citations: 30     Fields:    Translation:Humans
    229. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res. 2008 Jun 01; 14(11):3362-6. PMID: 18519764.
      Citations: 15     Fields:    Translation:Humans
    230. Karam JA, Margulis V, Montorsi F, Karakiewicz PI, Lotan Y, Kikuchi E, Weizer A, Zigeuner R, Bolenz C, Shariat SF. Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy--results from a multicenter study. Eur Urol. 2008 Oct; 54(4):961-3. PMID: 18485573.
      Citations: 2     Fields:    Translation:Humans
    231. Shariat SF, Jenkins A, Roehrborn CG, Karam JA, Stage KH, Karakiewicz PI. Features and outcomes of patients with grade IV renal injury. BJU Int. 2008 Sep; 102(6):728-33; discussion 733. PMID: 18435808.
      Citations: 10     Fields:    Translation:Humans
    232. Shariat SF, Karam JA, Raman JD. Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. Biomark Med. 2008 Apr; 2(2):165-80. PMID: 20477438.
      Citations: 2     Fields:    
    233. Karam JA, Sagalowsky AI. Minimally invasive radical cystectomy for bladder cancer? Lancet Oncol. 2008 Apr; 9(4):317-8. PMID: 18374289.
      Citations:    Fields:    Translation:Humans
    234. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, Shariat SF. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res. 2008 Mar 01; 14(5):1418-22. PMID: 18316564.
      Citations: 15     Fields:    Translation:Humans
    235. Fan J, Stanfield J, Guo Y, Karam JA, Frenkel E, Sun X, Hsieh JT. Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer. Clin Cancer Res. 2008 Feb 15; 14(4):1200-7. PMID: 18281555.
      Citations: 4     Fields:    Translation:HumansAnimals
    236. Svatek RS, Karam J, Karakiewicz PI, Gallina A, Casella R, Roehrborn CG, Shariat SF. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. J Urol. 2008 Feb; 179(2):478-84; discussion 484. PMID: 18076936.
      Citations: 6     Fields:    Translation:Humans
    237. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol. 2008 Jan; 18(1):1-8. PMID: 18090481.
      Citations: 24     Fields:    Translation:Humans
    238. Hsieh JT, Karam JA, Min W. Genetic and biologic evidence that implicates a gene in aggressive prostate cancer. J Natl Cancer Inst. 2007 Dec 19; 99(24):1823-4. PMID: 18073373.
      Citations: 4     Fields:    Translation:Humans
    239. Karam JA, Kabbani W, Sagalowsky AI. Pseudosarcomatous fibromyxoid tumor of the bladder. Urol Oncol. 2008 May-Jun; 26(3):291-4. PMID: 18452822.
      Citations: 2     Fields:    Translation:Humans
    240. Shariat SF, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int. 2008 Mar; 101(6):675-83. PMID: 17941930.
      Citations: 24     Fields:    Translation:Humans
    241. Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5377-84. PMID: 17875766.
      Citations: 6     Fields:    Translation:Humans
    242. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology. 2007 Sep; 70(3):482-6. PMID: 17905101.
      Citations: 22     Fields:    Translation:Humans
    243. Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4400-6. PMID: 17671122.
      Citations: 25     Fields:    Translation:HumansAnimals
    244. Shariat SF, Karam JA, Roehrborn CG. Blood biomarkers for prostate cancer detection and prognosis. Future Oncol. 2007 Aug; 3(4):449-61. PMID: 17661720.
      Citations: 10     Fields:    Translation:Humans
    245. Karam JA, Vazquez DV, Lin VK, Zimmern PE. Elastin expression and elastic fibre width in the anterior vaginal wall of postmenopausal women with and without prolapse. BJU Int. 2007 Aug; 100(2):346-50. PMID: 17532852.
      Citations: 18     Fields:    Translation:Humans
    246. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 2007 May 01; 67(6):614-22. PMID: 17299799.
      Citations: 58     Fields:    Translation:Humans
    247. Karam JA, Fan J, Stanfield J, Richer E, Benaim EA, Frenkel E, Antich P, Sagalowsky AI, Mason RP, Hsieh JT. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer. 2007 Apr 15; 120(8):1795-802. PMID: 17230511.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    248. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007 Feb; 8(2):128-36. PMID: 17267327.
      Citations: 65     Fields:    Translation:Humans
    249. Karam JA, Baker LA. Focal orchitis presenting as bilateral testicular masses. J Pediatr Urol. 2007 Aug; 3(4):337-9. PMID: 18947769.
      Citations: 2     Fields:    
    250. Chen H, Karam JA, Schultz R, Zhang Z, Duncan C, Hsieh JT. Cloning of mouse Dab2ip gene, a novel member of the RasGTPase-activating protein family and characterization of its regulatory region in prostate. DNA Cell Biol. 2006 Apr; 25(4):232-45. PMID: 16629596.
      Citations: 8     Fields:    Translation:AnimalsCells
    251. Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh JT. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol. 2006 Mar-Apr; 24(2):152-60. PMID: 16520279.
      Citations: 8     Fields:    Translation:Humans
    252. Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer. Eur Urol. 2006 Apr; 49(4):666-74. PMID: 16423446.
      Citations: 12     Fields:    Translation:Humans
    253. Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol. 2005 Sep; 48(3):424-31. PMID: 15963628.
      Citations: 4     Fields:    Translation:Humans
    254. Nasr R, El-Sabban ME, Dbaibo G, Kfoury Y, Arnulf B, Lepelletier Y, Hermine O, Bazarbachi A, Karam JA, Bex F, de Th? H. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene. 2005 Jan 13; 24(3):419-30. PMID: 15543232.
      Citations: 28     Fields:    Translation:HumansCells
    255. Benaim EA, Karam JA, Soboorian MH, Roehrborn CG, McConnell JD, Lin V. The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate. Prostate. 2004 Sep 01; 60(4):310-6. PMID: 15264242.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    256. Shulman MJ, Karam JA, Benaim EA. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology. 2004 Apr; 63(4):732-6. PMID: 15072890.
      Citations: 9     Fields:    Translation:Humans
    257. Karam JA, Baker LA. Images in clinical medicine. True hermaphroditism. N Engl J Med. 2004 Jan 22; 350(4):393. PMID: 14736931.
      Citations: 1     Fields:    Translation:Humans
    258. Karam JA, Mason RP, Koeneman KS, Antich PP, Benaim EA, Hsieh JT. Molecular imaging in prostate cancer. J Cell Biochem. 2003 Oct 15; 90(3):473-83. PMID: 14523981.
      Citations: 7     Fields:    Translation:HumansAnimals
    259. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Therapeutic Advances in Urology. 8:130-141.
    260. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology: Seminars and Original Investigations.
    261. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus. BJU International.
    262. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene.
    263. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma. World Journal of Urology. 1-8.
    264. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. European Urology.
    265. Genomic investigation of etiologic heterogeneity. BMC Medical Research Methodology. 14.
    266. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic Renal cell carcinoma. Cancer immunology research. 3:1017-1029.
    267. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. Urologic Oncology: Seminars and Original Investigations. 34:167.e9-167.e16.
    268. Cytoreductive nephrectomy for metastatic renal cell carcinoma. Clinical Advances in Hematology and Oncology. 14:696-703.
    269. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney. BJU International.
    270. Biomarkers in Genitourinary Cancers. European Urology. 71:247-248.
    271. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC). BJU International. 117:629-635.
    272. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma Urological oncology. BMC Urology. 15:1-8.
    273. Anti-cancer strategy of transitional cell carcinoma of bladder based on induction of different types of programmed cell deaths. 25-50.
    274. Management of non-clear cell renal cell carcinoma. 373-385.
    275. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations. 33:427.e17-427.e23.
    276. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN). European Urology.
    277. Cytoreductive surgery in the era of targeted molecular therapy. Translational Andrology and Urology. 4:301-309.
    278. Management of the Incidental Adrenal Mass. European Urology Focus. 1:223-230.
    279. Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. European Urology Focus. 2:204-209.
    280. Epigenetics in prostate cancer. 213-242.
    281. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU International.
    282. Benign prostatic hyperplasia. Journal of Urology. 173:1266-1267.
    283. DNA methylation signature reveals cell ontogeny of renal cell carcinomas. Clinical Cancer Research. 22:6236-6246.
    284. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. European Urology. 66:874-880.
    285. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. 33:495.e15-495.e22.
    286. Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology. 94:314.e1-314.e7.
    287. Developing a clear path forward for non-clear-cell renal carcinoma. Journal of Clinical Oncology. 34:3825-3826.
    288. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. European Urology.
    289. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. The Lancet Oncology. 17:1672-1682.
    290. Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract. World Journal of Urology. 1-7.
    291. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. Journal of Urology.
    292. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 7:86280-86289.
    293. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma. World Journal of Urology. 1-8.
    294. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma. Modern Pathology. 28:1225-1235.
    295. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology. 1-9.
    296. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World Journal of Urology. 1-10.
    297. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mrcc) treated with sunitinib. Urology Case Reports. 3:18-20.
    298. Postoperative surveillance protocols for renal cell carcinoma. 283-305.
    299. Metastases to the kidney. BJU International.
    300. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation. Journal of Urology.
    301. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. British Journal of Cancer. 116:77-84.
    302. Urine cytology and commercially available urine-based markers for monitoring of bladder urothelial carcinoma. Laboratory Medicine. 38:48-52.
    303. Secondary malignancies diagnosed using kidney needle core biopsies. Human Pathology. 52:55-60.
    304. Role of targeted therapy in combination with surgery in renal cell carcinoma. International Journal of Urology. 23:5-12.
    305. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology. 1-7.
    306. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations. 33:166.e21-166.e29.
    307. Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. European Urology.
    308. True Hermaphroditism. New England Journal of Medicine. 350:393.
    309. Intratumoral heterogeneity. Cancer.
    310. Management and outcomes of patients with renal medullary carcinoma. BJU International.
    311. Bladder cancer screening and future directions in urine-based markers for bladder urothelial carcinoma. Laboratory Medicine. 38:116-120.
    312. Genomic DNA hypomethylation and risk of renal cell carcinoma. Clinical Cancer Research. 22:2074-2082.
    KARAM's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (633)
    Explore
    _
    Co-Authors (129)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _